Mubadala Bio Appoints New CEO to Lead Global Life Sciences Growth
<h3>Mubadala Bio Names New Leadership to Drive Global Expansion</h3><p>Mubadala Bio, the life sciences subsidiary of Abu Dhabi’s Mubadala Investment Company, has announced a significant leadership reshuffle aimed at strengthening its global healthcare footprint. The company has appointed Dr. Essam Mohamed as its new Chief Executive Officer and Hamad Husein Al Marzooqi as Deputy CEO. These appointments underscore Mubadala Bio’s commitment to advancing pharmaceutical innovation, ensuring national drug security, and expanding its influence across global markets.</p><h3>New CEO Brings Decades of Expertise</h3><p>Dr. Essam Mohamed, who steps in as CEO, brings with him more than 30 years of experience in the pharmaceutical and life sciences industry. His career spans leadership roles in multinational corporations, regulatory reforms, and the successful establishment of regional startups. Having overseen large-scale corporate transformations, Dr. Mohamed is widely recognized for his ability to balance operational efficiency with innovation in drug development.</p><p>In his new role, Dr. Mohamed will be responsible for steering Mubadala Bio’s operations, guiding its long-term strategy, and driving the company’s next phase of growth across both regional and international markets.</p><p>“Our mission is to accelerate healthcare innovation and expand access to life-saving medicines,” Dr. Mohamed said in a statement. “I am honored to lead Mubadala Bio at such a pivotal time, as we strengthen the UAE’s role in global life sciences.”</p><h3>Strengthening the Leadership Team</h3><p>Alongside Dr. Mohamed, Mubadala Bio has named Hamad Husein Al Marzooqi as Deputy CEO. Al Marzooqi, who has nearly 20 years of experience spanning the UAE, Russia, Brazil, and the UK, most recently headed Mubadala’s Life Sciences Cluster. His background in global markets and investment strategy positions him to support the company’s expansion across emerging and established healthcare ecosystems.</p><p>The leadership changes also include key appointments in finance and logistics. Atif Azeem, with nearly three decades of financial and investment expertise, has been named Chief Financial Officer. Meanwhile, Khalid Abdallah Al-Kaf takes on the role of General Manager of Pharma Logistics, bringing with him 20 years of experience in logistics, IT, and digital transformation.</p><h3>A Message from Mubadala Leadership</h3><p>Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, welcomed the new leadership team, saying:<br>“We are proud to welcome leaders of this caliber to Mubadala Bio. Their collective experience and vision will strengthen our capabilities, drive innovation, and support our mission to deliver better health for all.”</p><p>The leadership transition reflects Mubadala Bio’s strategy of aligning world-class talent with its ambitious healthcare agenda—both within the UAE and globally.</p><h3>Strategic Focus: Biopharma and Logistics</h3><p>Mubadala Bio operates through two primary verticals:</p><p><strong>Integrated Biopharma</strong> – focusing on the local production of pharmaceuticals, ensuring a sustainable supply of essential medicines, and enhancing the UAE’s national drug security.</p><p><strong>Pharma Logistics</strong> – leveraging advanced logistics and digital systems to improve drug distribution efficiency and ensure timely access to critical medications.</p><p>This dual approach allows the company to balance domestic healthcare priorities with international opportunities, particularly in Asia, Africa, and Europe, where demand for pharmaceutical partnerships and reliable supply chains is growing rapidly.</p><h3>Driving Economic Diversification and Drug Security</h3><p>Mubadala Bio plays a central role in supporting the UAE’s broader goals of healthcare innovation and economic diversification. By investing in pharmaceutical manufacturing and advanced logistics infrastructure, the company is helping to reduce reliance on imports and create a resilient national healthcare system.</p><p>At the same time, Mubadala Bio is pursuing international collaborations that will strengthen the UAE’s reputation as a hub for medical innovation. Partnerships, like its recent tie-up with Borouge to enhance healthcare manufacturing, demonstrate the company’s commitment to advancing global health solutions while reinforcing local capabilities.</p><h3>Looking Ahead</h3><p>With its new leadership team in place, Mubadala Bio is well-positioned to expand its global presence and play a defining role in shaping the future of healthcare. By combining world-class expertise with a clear strategic vision, the company is set to deliver innovative therapies, improve access to medicines, and contribute to the UAE’s growing influence in life sciences.</p><p>The appointments of Dr. Mohamed and Al Marzooqi mark not just a change in leadership, but also a new chapter in Mubadala Bio’s journey—one that aligns with the UAE’s ambition to be at the forefront of healthcare transformation worldwide.</p>